Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations

Cancer Discovery

Volumn 5, Issue 4, 2015, Pages 358-367

  Ahronian, Leanne G ^a,b   Sennott, Erin M ^a,b   Van Allen, Eliezer M ^c,d   Wagle, Nikhil ^c,d   Kwak, Eunice L ^a,b   Faris, Jason E ^a,b   Godfrey, Jason T ^a   Nishimura, Koki ^a   Lynch, Kerry D ^e   Mermel, Craig H ^a,d   Lockerman, Elizabeth L ^a   Kalsy, Anuj ^a   Gurski, Joseph M ^a,b   Bahl, Samira ^d   Anderka, Kristin ^d   Green, Lisa M ^d   Lennon, Niall J ^d   Huynh, Tiffany G ^e   Mino Kenudson, Mari ^e   Getz, Gad ^a,d   Dias Santagata, Dora ^e   Iafrate, A John ^e   Engelman, Jeffrey A ^a,b   Garraway, Levi A ^c,d   Corcoran, Ryan B ^a,b   more..

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A RAF KINASE; B RAF KINASE; B RAF KINASE INHIBITOR; CARCINOEMBRYONIC ANTIGEN; DABRAFENIB; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PANITUMUMAB; SELUMETINIB; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; MAP2K1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN KINASE INHIBITOR; PROTEIN P21;

ARTICLE; CANCER GROWTH; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; GENE DOSAGE; GENE FREQUENCY; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR BIOPSY; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; GENE AMPLIFICATION; GENETICS; METABOLISM; MUTATION; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GENE AMPLIFICATION; HUMANS; MAP KINASE KINASE 1; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUTATION; ONCOGENE PROTEIN P21(RAS); PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSCRIPTIONAL ACTIVATION;

EID: 84933040790     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-14-1518     Document Type: Article

References (25)

1. D avies H, B ignell G R, C ox C, S tephens P, E dkins S, C legg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949 - 54.
2. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009; 27: 5931-7.
3. Montagut C, Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 2009; 283: 125-34.
4. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-19.
5. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014; 371: 1877-88.
6. Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Lee RJ, et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol 28: 15s, 2010 (suppl; abstr 3534).
7. Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal 2010; 3: ra84.
8. Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012; 2: 227-35.
9. Montero-Conde C, Ruiz-Llorente S, Dominguez JM, Knauf JA, Viale A, Sherman EJ, et al. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov 2013; 3: 520-33.
10. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483: 100-3.
11. Corcoran RB, Atreya CE, Falchook GS, Infante JR, Hamid O, Messersmith WA, et al. Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): updated efficacy and biomarker analysis. J Clin Oncol 32: 5s, 2014 (suppl; abstr 3517).
12. Bendell JC, Atreya CE, Andre T, Tabernero J, Gordon MS, Bernards R, et al. Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC). J Clin Oncol 32: 5s, 2014 (suppl; abstr 3515).
13. Tabernero J, Chan E, Baselga J, Blay J-Y, Chau I, Hyman DM, et al. VE-BASKET, a Simon 2-stage adaptive design, phase II, histologyindependent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC). J Clin Oncol 32: 5s, 2014 (suppl; abstr 3518).
14. Geel RV, Elez E, Bendell JC, Faris JE, Lolkema MPJK, Eskens F, et al. Phase I study of the selective BRAFV600inhibitor encorafenib (LGX818) combined with cetuximab and with or without the {alpha}- specific PI3K inhibitor BYL719 in patients with advanced BRAFmutant colorectal cancer. J Clin Oncol 32: 5s, 2014 (suppl; abstr 3514).
15. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468: 973-7.
16. Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 2014; 4: 94-109.
17. Hatzivassiliou G, Liu B, O'Brien C, Spoerke JM, Hoeflich KP, Haverty PM, et al. ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol Cancer Ther 2012; 11: 1143-54.
18. Morris EJ, Jha S, Restaino CR, Dayananth P, Zhu H, Cooper A, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov 2013; 3: 742- 50.
19. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486: 532-6.
20. Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 2012; 3: 724.
21. Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor- Weiner A, et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov 2014; 4: 61-8.
22. Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, et al. Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin Cancer Res 2014; 20: 2264-75.
23. Imielinski M, Greulich H, Kaplan B, Araujo L, Amann J, Horn L, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma . J Clin Invest 2014; 124: 1582-6.
24. Little AS, Balmanno K, Sale MJ, Newman S, Dry JR, Hampson M, et al. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci Signal 2011; 4: ra17.
25. Van Allen EM, Wagle N, Stojanov P, Perrin DL, Cibulskis K, Marlow S, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med 2014; 20: 682-8.